Clouding the G-7 gathering, which represents the world's major industrial economies, are the tit-for-tat tariffs between Washington and Beijing.Politicsread more
The Goldman Sachs technology M&A team, led by Sam Britton, has cashed in on its software focus and decades of experience to dominate 2019's biggest deals.Technologyread more
American small and medium-size companies that rely on China are scrambling to adjust their business plans in response to the escalating trade war.Traderead more
Here are the products that stand to be the most affected by China's new tariffs on $75 billion worth of U.S. goods.Marketsread more
The summit comes amid fears over a global economic slowdown, and U.S. tensions over trade allies, Iran and Russia.Politicsread more
Carl Medlock used to work at Tesla. Now he's one of the few people in the U.S. that can fix the company's original Roadster electric vehicles.Technologyread more
The world's second biggest economy is past a point where it cannot ignore its enormous debt anymore, according to an analyst.China Economyread more
Trump does have some powerful tools that would not require approval from U.S. Congress.Politicsread more
Stocks dropped after Donald Trump ordered that U.S. manufacturers find alternatives to their operations in China.US Marketsread more
As demand for lab monkeys continues to rise, U.S. scientists are reporting delays in research projects because they can't obtain enough animals, according to the National...Politicsread more
The European Union will respond in kind if the U.S. imposes tariffs on France over digital tax plan, EU chief Donald Tusk told G-7.Technologyread more
SAO PAULO, May 16 (Reuters) - Japan's Takeda Pharmaceutical Co expects to receive binding offers for its Latin American business by the end of May, three sources with knowledge of the matter said.
Brazilian pharmaceutical group EMS is considered the front-runner in the process, but Blackstone-backed Brazilian investment firm Patria Investments may also deliver a bid, sources added asking for anonymity as discussions are still private.
Private equity firms such as Advent International Corp and CVC Capital Partners, and strategic bidders such as Brazilian pharmaceutical company Eurofarma, have analyzed the asset, but are not expected to deliver binding offers to the investment banking unit of Bank of America, which is Takeda's advisor.
EMS, Patria, Advent, CVC and Bank of America declined to comment. Takeda did not immediately comment.
Latin America represents around 4% of Takeda's revenue. The company sells in the region vaccines, oncology, gastroenterology and over-the-counter products. Takeda expects the business to fetch around $1 billion, the sources added.
A fourth source with knowledge of the matter said EMS is very interested in the Latin American operations after having acquired last year from Takeda its Brazil's Multilab unit, located in the southern region of the country.
Patria, in which Blackstone Group LP has a 40 percent stake, owns in Brazil Natulab, a pharmaceutical company specialized in over-the-counter drugs and vitamins.
Takeda Pharmaceutical has been selling assets after the $59 billion purchase of Shire Plc and targets $10 billion in divestments to cut its debt. The company predicted this week a loss due to costs associated with the acquisition.
Earlier this month, Takeda agreed to sell its dry eye drug Xiidra to Swiss drugmaker Novartis for up to $5.3 billion, and TachoSil, a surgical patch for bleeding control, to Johnson & Johnson's for $400 million.
(Reporting by Tatiana Bautzer Editing by Nick Zieminski)